

Name	Dr. Rajpal Srivastav	
Designation	Assistant Professor-III	
E-mail ID	rsrivastav2@amity.edu	

Research Area(s)	Drug discovery, Host-pathogen interactions, Proteogenomics, Replication mechanistics.
-------------------------	--

Educational Qualifications:

Name of College / University/Institution	Degree	Year
University of Delhi, New Delhi	B.Sc	2005
Indian Institute of Technology Roorkee, Roorkee	M.Sc	2007
CSIR-Institute of Genomics & Integrative Biology, New Delhi	Ph.D	2013

Experience (in chronological order)

Designation	Type of post held	Name of the Institute	Year
Assistant Professor-III	Research & Teaching	Amity Institute of Biotechnology, Amity University Uttar Pradesh, Noida	2022 - Current
DST INSPIRE Faculty	Research & Teaching	Amity Institute of Biotechnology, Amity University Uttar Pradesh, Noida	2017-22
Research Associate	Research	Bioinnovat, Gurugram, Haryana	2016-17
Post-doctoral fellow	Research	DBT-Translational Health Science & Technology Institute, Haryana	2013-16

Publications (24)

1. Radhakrishnan A, Gangopadhyay R, Sharma C, Kapardar RK, Sharma NK, **Srivastav R** (2024). Unwinding Helicase MCM Functionality for Diagnosis and Therapeutics of Replication Abnormalities Associated with Cancer: A Review. *Mol Diagn Ther.* 28, 249–264. <https://doi.org/10.1007/s40291-024-00701-5> . (IF 4.1)
2. Radhakrishnan A, Sharma C, Malviya VN, **Srivastav R** (2024). Deciphering the molecular functionality of Cdc45 in replisomal complex. *Biochemistry and Biophysics Reports*, 37,101643, ISSN 2405-5808, <https://doi.org/10.1016/j.bbrep.2024.101643> (IF 3.0)
3. Chauhan, A., Yadav, M., Chauhan, R. **Srivastav R** et al (2024). Exploring the Potential of Ellagic Acid in Gastrointestinal Cancer Prevention: Recent Advances and Future Directions. *Oncol Ther* (2024). <https://doi.org/10.1007/s40487-024-00296-1> (IF 3.2)
4. Singh VK, Hu X-H, Singh AK, Solanki MK, Vijayaraghavan P, **Srivastav R**, Joshi NK, Kumari M, Singh SK, Wang Z and Kumar A (2024). Precision nutrition-based strategy for management of human diseases and healthy aging: current progress and challenges forward. *Front. Nutr.* 11:1427608. <https://doi.org/10.3389/fnut.2024.1427608> (IF 4.0)
5. Radhakrishnan A, Shakshi, Nandini R, Kumar A, Kapardar RK, **Srivastav R** (2024). Role of MATE Transporters in Xenobiotics Tolerance. (Eds) *Microbes Based Approaches for the Management of Hazardous Contaminants*. Pp 411-419. John Wiley & Sons, Inc. <https://doi.org/10.1002/9781119851158.ch27>
6. Shakshi, Gaba A, Radhakrishnan A, **Srivastav R** (2024). Use of microdilution methods to assess anti-microbial inhibition. UG research conclave, ISBN: 978-93-93873-82-8, *Renova International Pub.*

7. Radhakrishnan, A; Kapardar, RK; **Srivastav, R.** (2024). Targeting mycobacterial efflux system for combating anti-microbial resistance. Research Symposium. 27.
<https://scholarworks.utrgv.edu/somrs/2024/talks/27>
8. Nandani R, Shakshi, Radhakrishnan A, Kumar R, Kapardar RK, **Srivastav R** (2024): Perspectives of probiotics in the next-generation sequencing era. *Academic Press*, 403-416, ISBN 9780443217814, <https://doi.org/10.1016/B978-0-443-21781-4.00007-4>.
9. Chattopadhyay R, **Srivastav R** (2024). Mechanisms and Applications of CRISPR mediated Gene Silencing. *Intern Res J of Eng & Tech IRJET*; 11(3). Vol 11, I
<https://www.irjet.net/archives/V11/i3/IRJET-V11I3186.pdf>
10. Radhakrishnan R, Kapil T, Kapardar R, **Srivastav R** (2023). Microbiome additive therapy for the human health. *Microbiome Therapeutics, Academic Press*, Pages 41-61. <https://doi.org/10.1016/B978-0-323-99336-4.00011-2>
11. Radhakrishnan A, Balaganesh P, Vasudevan M, Natarajan N, Chauhan A, Arora J, Ranjan A, Rajput VD, Sushkova S, Minkina T, Basniwal RK, Kapardar R, **Srivastav R** (2023). Bioremediation of Hydrocarbon Pollutants: Recent Promising Sustainable Approaches, Scope, and Challenges. *Sustainability*, 15(7), 5847. (IF 4.0)
12. Tandon C, **Srivastav R** (2022). Advances in Proteomics Approaches and Chronic Kidney Disease. In: Sobti, R., Sobti, A. (eds) *Biomedical Translational Research*. Springer, Singapore.
https://doi.org/10.1007/978-981-16-4345-3_14
13. Radhakrishnan A, Kakkar P, Tandon C, **Srivastav R** (2022). Fecal Microbiome Transplantation: An offhand recipe for microbiome therapeutics, *Comprehensive Gut Microbiota*, vol. 3. Elsevier, pp 246–256

14. Kumar D, Baligar P, **Srivastav R**, Narad P, Raj S, Tandon C, Tandon S (2021). Stem cell based preclinical drug development and toxicity prediction. *Curr Pharm Des.* 27(19):2237-2251 (**I.F 3.0**)
15. Suneja G, **Srivastav R** (2021). Impact of Microbial Genome Sequencing Advancements in Understanding Extremophiles. *Extreme Environments, Unique Ecosystems - Amazing Microbes*, Ed-1; 13, CRC Press; Taylor & Francis.
16. Radhakrishanan A, Srivastav C, Sharma C, Tandon C, **Srivastav R** (2021) Determinants influencing the relapse of SARS-CoV-2 infections in COVID-19 pandemic. *J pathol. comm. disease & prev. medicine* 3(1) 9-19.
17. Nandi V, Nandy N, **Srivastav R** (2021). Gamma-aminobutyric acid modulates the neurotransmission for healthy brain functioning and survival. *J Pharma Sci Med Technol.* 3: 1.
18. **Srivastav R***, Sharma R, Tandon S, Tandon C (2019). Role of DHH superfamily proteins in nucleic acids metabolism and stress tolerance in prokaryotes and eukaryotes. *Int J Biol Macromol*; 127:66-75. (***Corresponding author**) (**I.F 6.95**)
19. Suneja G, **Srivastav R**, (2019). Recent advances in microbial genome sequencing. (eds) *Microbial Genomics in Sustainable Agroecosystems*. Pp131-134, Springer
20. Grover R, Burse S, Shankrit S, Aggarwal A, Kirty K, Narta K, **Srivastav R**, Ray AK, Malik G, Vats A, Motiani RK, Thukral L, Roy SS, Bhattacharya S, Sharma R, Natarajan K, Mukerji M, Pandey R, Gokhale RS, Natarajan VT (2019). Myg1 exonuclease couples the nuclear and mitochondrial translational programs through RNA processing. *Nucleic Acids Res.* 47, 11:5852–5866. (**I.F 14.9**)

	<p>21. Madhavi A, Hingane S, Srivastav R, Joshi N, Subramani C, Muthumohan R, khasa R, Varshney S, Kalia M, Vrati S, Surjit M, Ranjith-Kumar CT (2017). A Screen for novel hepatitis C virus RdRp inhibitor identifies a broad-spectrum anti-viral compound. <i>Scientific Reports</i>. 7(1):5816. (I.F 5.2)</p> <p>22. Srivastav R, Kumar D, Grover A, Singh A, Manjasetty B, Sharma R, Taneja B (2014). Unique subunit packing in mycobacterial nanoRNase leads to alternate substrate recognitions in DHH phosphodiesterases. <i>Nucleic Acids Res</i>, 42, (12) 7894-7910. (I.F 14.9)</p> <p>23. Srivastav R. Novel activity of NrnA homolog signifies engineering at cellular level (2014). <i>RRJoBI</i>;1(1)46-48</p> <p>24. Srivastav R, Singh A, Jangir PK, Kumari C, Muduli S, Sharma R (2013). Genome sequence of <i>Staphylococcus massiliensis</i> strain S46 isolated from surface of healthy human skin. <i>Genome Announc</i> 1(4):e00553-13</p>
<p>Awards & Honors</p>	<ul style="list-style-type: none"> • DST INSPIRE Faculty Award • DS Kothari Post-doctoral Fellowship • CSIR- Senior Research Fellowship • CSIR- Junior Research Fellowship • CSIR-UGC-NET-Lectureship • PG-DBT Fellowship, IIT Roorkee
<p>Memberships of professional bodies</p>	<ul style="list-style-type: none"> • Proteomics Society, India • Indian Association for Cancer Research • Association of Microbiologists of India